Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.33 |
| ▸ | CA12 | O43570 | 2/20 | 0.33 |
| ▸ | CA1 | P00915 | 2/20 | 0.33 |
| ▸ | CA2 | P00918 | 2/20 | 0.33 |
| ▸ | CA9 | Q16790 | 2/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | OGA | O60502 | 1/20 | 0.32 |
| ▸ | CHRM2 | P08172 | 5/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.31 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.31 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.31 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14477774 | 0.84 | CA2 (0.45) | TSHRCYP2D6CA12CA1CA2 | |
| SCHEMBL26499159 | 0.84 | CA2 (0.45) | TSHRCYP2D6CA12CA1CA2 | |
| SCHEMBL9910565 | 0.78 | TSHR (0.36) | TSHRCYP2D6CA12CA1CA2 | |
| SCHEMBL9910569 | 0.78 | TSHR (0.36) | TSHRCYP2D6CA12CA1CA2 | |
| SCHEMBL17972374 | 0.78 | TSHR (0.36) | TSHRCYP2D6CA12CA1CA2 | |
| SCHEMBL15489375 | 0.78 | TSHR (0.36) | TSHRCYP2D6CA12CA1CA2 | |
| SCHEMBL6974952 | 0.78 | TSHR (0.36) | TSHRCYP2D6CA12CA1CA2 | |
| SCHEMBL11949492 | 0.78 | TSHR (0.51) | TSHRCYP2D6CA12CA1CA2 | |
| SCHEMBL12450450 | 0.78 | TSHR (0.51) | TSHRCYP2D6CA12CA1CA2 | |
| SCHEMBL21859074 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9688707-B2 | Bicyclic morpholino compounds and oligomeric compounds prepared therefrom | IONIS PHARMACEUTICALS, INC. (US) | 2017-06-27 | — | — | US | disclosed |
| US-20160186175-A1 | BICYCLIC MORPHOLINO COMPOUNDS AND OLIGOMERIC COMPOUNDS PREPARED THEREFROM | IONIS PHARMACEUTICALS, INC. (US) | 2016-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160186175-A1 | BICYCLIC MORPHOLINO COMPOUNDS AND OLIGOMERIC COMPOUNDS PREPARED THEREFROM | HNRNPM, UPF1, METTL16 | TSHR 4646/4885CYP2D6 4547/4885CA12 4525/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.